Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.52 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.52 |
| ▸ | GABRP | O00591 | 1/20 | 0.46 |
| ▸ | GABRD | O14764 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.46 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.46 |
| ▸ | GABRE | P78334 | 1/20 | 0.46 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.46 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.46 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.46 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956273 | 1.00 | KMT2A (0.54) | KMT2ACYP2A6IMPDH2GABRPGABRD | |
| SCHEMBL11167122 | 0.88 | KMT2A (0.50) | KMT2ACYP2A6IMPDH2GABRPGABRD | |
| SCHEMBL27537587 | 0.74 | CYP2A6 (0.43) | KMT2ACYP2A6IMPDH2GABRPGABRD | |
| SCHEMBL13486538 | 0.74 | HDAC1 (0.46) | KMT2AMEN1NPC1RAB9APSMD14 | |
| SCHEMBL23600364 | 0.74 | KDM4E (0.44) | KMT2AKDM4EMEN1NPC1RAB9A | |
| SCHEMBL8325698 | 0.74 | APP (0.59) | KMT2AKDM4EMEN1NPSR1PSMD14 | |
| SCHEMBL23582854 | 0.73 | PIM1 (0.38) | KMT2AGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL31631157 | 0.73 | CYP2A6 (0.42) | KMT2ACYP2A6IMPDH2GABRPGABRD | |
| SCHEMBL23295564 | 0.73 | CYP2A6 (0.42) | KMT2ACYP2A6IMPDH2GABRPGABRD | |
| SCHEMBL29958165 | 0.73 | CYP2A6 (0.42) | KMT2ACYP2A6IMPDH2GABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092034-A1 | 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME | KULEON LLC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20250340513-A1 | NEUROPLASTOGENS AND NON-HALLUCINOGENIC SEROTONIN 5-HT2A/2C RECEPTOR MODULATORS | KULEON LLC (US) | 2025-11-06 | — | — | US | disclosed |
| US-12441683-B2 | 7-methyl indole analogs and dosage forms containing the same | Kuleon, LLC (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250282722-A1 | 7-METHYL INDOLE ANALOGS AND DOSAGE FORMS CONTAINING THE SAME | KULEON LLC (US) | 2025-09-11 | — | — | US | disclosed |
| US-12344582-B2 | Mixed serotonin 5-HT2A/2C receptor agonists and methods for treating pain and depression | Kuleon, LLC (US) | 2025-07-01 | — | — | US | disclosed |
| US-12275701-B2 | Neuroplastogens and non-hallucinogenic serotonin 5-HT2A receptor modulators | Kuleon, LLC (US) | 2025-04-15 | — | — | US | disclosed |
| US-20250091991-A1 | MIXED SEROTONIN 5-HT2A/2C RECEPTOR AGONISTS AND METHODS FOR TREATING PAIN AND DEPRESSION | Kuleon, LLC (US) | 2025-03-20 | — | — | US | disclosed |
| US-12187678-B2 | Methods of treating psychological disorders through the administration of serotonin 5-HT2C receptor modulators | Kuleon, LLC (US) | 2025-01-07 | — | — | US | disclosed |
| EP-3440097-B1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL MYERS SQUIBB CO (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20240343690-A1 | Neuroplastogens and Non-Hallucinogenic Serotonin 5-HT2A Receptor Modulators | KULEON LLC (US) | 2024-10-17 | — | — | US | disclosed |
| US-20070123532-A1 | PIPERAZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2007-05-31 | — | — | US | disclosed |
| US-20070123535-A1 | 3-Amino-1-arylpropyl azaindoles and uses thereof | ROCHE PALO ALTO LLC | 2007-05-31 | — | — | US | disclosed |
| US-20070123535-A1 | 3-Amino-1-arylpropyl azaindoles and uses thereof | ROCHE PALO ALTO LLC | 2007-05-31 | — | — | US | disclosed |
| US-20070123535-A1 | 3-Amino-1-arylpropyl azaindoles and uses thereof | ROCHE PALO ALTO LLC | 2007-05-31 | — | — | US | disclosed |
| CN-1900080-A | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LTD (GB) | 2007-01-24 | — | — | CN | disclosed |
| US-7166598-B2 | e.g 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[3-[(2-methoxyethoxy)-methoxy]-4-methylbenzyl]-4-[2-[(3R)-3-methoxymethyl-morpholino]ethyl]piperazine; treating or preventing Tachykinin-mediated diseases such as asthma, emesis, an anxiety disorder, pollakiuria, urinary incontinence and irritable bowel syndrome | ASTELLAS PHARMA INC. (JP) | 2007-01-23 | — | — | US | disclosed |
| CN-1269822-C | Inhibitors of kruenza protease and other cysteine proteases | AMURA THERAPEUTICS LTD (GB) | 2006-08-16 | — | — | CN | disclosed |
| EP-1140924-B1 | PIPERAZINE DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2006-03-22 | — | — | EP | disclosed |
| US-20060014948-A1 | e.g 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[3-[(2-methoxyethoxy)-methoxy]-4-methylbenzyl]-4-[2-[(3R)-3-methoxymethyl-morpholino]ethyl]piperazine; treating or preventing Tachykinin-mediated diseases in humans or animals | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2006-01-19 | — | — | US | disclosed |
| CN-1486320-A | Inhibitors of kruenza protease and other cysteine proteases | ��ķ��ҽ������˾ | 2004-03-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014948-A1 | e.g 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[3-[(2-methoxyethoxy)-methoxy]-4-methylbenzyl]-4-[2-[(3R)-3-methoxymethyl-morpholino]ethyl]piperazine; treating or preventing Tachykinin-mediated diseases in humans or animals | PKD2, TAC3, PKD1 | KMT2A 709/4885CYP2A6 3046/4885IMPDH2 3600/4885 |
| US-20260092034-A1 | 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME | HTR2C, HTR7, HTR6 | KMT2A 1166/4885CYP2A6 242/4885IMPDH2 3747/4885 |
| US-20250282722-A1 | 7-METHYL INDOLE ANALOGS AND DOSAGE FORMS CONTAINING THE SAME | HTR7, HTR2C, HTR1A | KMT2A 417/4885CYP2A6 351/4885IMPDH2 630/4885 |
| US-12441683-B2 | 7-methyl indole analogs and dosage forms containing the same | HTR7, HTR2C, HTR1A | KMT2A 417/4885CYP2A6 351/4885IMPDH2 630/4885 |
| US-12275701-B2 | Neuroplastogens and non-hallucinogenic serotonin 5-HT2A receptor modulators | HTR2A, HTR2C, HTR1A | KMT2A 545/4885CYP2A6 1856/4885IMPDH2 2537/4885 |
| US-12187678-B2 | Methods of treating psychological disorders through the administration of serotonin 5-HT2C receptor modulators | HTR2C, HTR2A, HTR3B | KMT2A 349/4885CYP2A6 1416/4885IMPDH2 2671/4885 |
| US-20070123535-A1 | 3-Amino-1-arylpropyl azaindoles and uses thereof | CNKSR1, AR, CYP3A43 | KMT2A 1129/4885CYP2A6 43/4885IMPDH2 1651/4885 |
| US-20250340513-A1 | NEUROPLASTOGENS AND NON-HALLUCINOGENIC SEROTONIN 5-HT2A/2C RECEPTOR MODULATORS | HTR2A, HTR2C, HTR3A | KMT2A 523/4885CYP2A6 1646/4885IMPDH2 2424/4885 |
| US-20070123532-A1 | PIPERAZINE DERIVATIVES | PKD2, SSTR5, IL5 | KMT2A 1454/4885CYP2A6 2786/4885IMPDH2 1135/4885 |
| US-12344582-B2 | Mixed serotonin 5-HT2A/2C receptor agonists and methods for treating pain and depression | HTR2A, HTR2C, HTR3A | KMT2A 666/4885CYP2A6 1179/4885IMPDH2 1919/4885 |
| US-20240343690-A1 | Neuroplastogens and Non-Hallucinogenic Serotonin 5-HT2A Receptor Modulators | HTR2A, HTR2C, HTR1A | KMT2A 545/4885CYP2A6 1856/4885IMPDH2 2537/4885 |
| US-20250091991-A1 | MIXED SEROTONIN 5-HT2A/2C RECEPTOR AGONISTS AND METHODS FOR TREATING PAIN AND DEPRESSION | HTR2A, HTR2C, HTR3A | KMT2A 666/4885CYP2A6 1179/4885IMPDH2 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.